Two drugs sent into the spinal fluid for high-grade glioma that came back
Original title: Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early safety test in people.
Status: Enrolling by invitation. It is only taking people the trial team invites. You cannot sign up for this one directly.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests two drugs placed into the fluid around the brain and spine.
Who this trial is for. This trial is for people whose high-grade glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary has come back. It tests two drugs, azacitidine and nivolumab, given into the spinal fluid at the same time.
Where it stands. This is a first-stage trial. Everyone in it gets the same treatment. The team is checking safety and looking for early signs the drugs help. The trial has not reported results.
What this means, and what it doesn't
What it could mean: Someone whose high-grade glioma: A tumor that starts in the glial cells. Those are the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4. The grade says how the tumor is expected to act. See the glossary has come back might ask their care team about trials like this one. The care team can talk through whether it makes sense to look into.
What it doesn't mean: This does not mean the treatment works. A trial is a test, not proven care. Being in one is not a promise of benefit. It is not a cure.
Source: ClinicalTrials.gov, October 27, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.